While 2020 is certainly a hard year to beat, 2021 has so far recorded a respectable amount of biopharma deals and is on track to exceed every other year.
With one completed med-tech merger ranking within the BioWorld Top 10 list for highest value, and two others set to join the list in coming months, 2021 is turning out to be the strongest M&A year for the industry to date.
Continuing an upward trajectory, BioWorld’s Drug Developers Index (BDDI) has climbed more than 10% since the start of this year, following sharp drops at the end of March and May. Shares began to rebound in June and the index has shown a steady incline, similar with the Nasdaq Biotechnology Index, which is currently up 12%.
With financings falling just shy of last year, the med-tech industry has raised a total of $41.3 billion so far in 2021 through 494 financings. That is down roughly 3% from the 513 financings worth $42.46 billion by this point in 2020. Most of the money last year came through follow-on offerings and private placements, with IPOs and venture capital rounds making up only 26% of the total.
RSS
